Abstract: The present invention relates to the use of Fosfestrol (diethylstilbestrol diphosphate) in a method of curative or palliative treatment of prostate cancer in male mammals, said method comprising orally administering Fosfestrol in a daily dosage of at least 1,000 mg. The inventors have discovered that Fosfestrol when administered in very high oral dosages is effective in the treatment of prostate cancer, especially hormone resistant prostate cancer, without giving rise to serious side effects, such as thromboembolic toxicity or mortality. The invention further provides an oral dosage unit comprising at least 500 mg, of Fosfestrol.

Abstract: The invention relates to the use of Sulfestrol (diethylstilbestrol sulfate) in a method of curative or palliative treatment of cancer in a mammal. The inventors have unexpectedly found that Sulfestrol can suitably be employed as an effective drug in the treatment of cancer in mammals. The inventors have further discovered that Sulfestrol can be administered even in high dosages without giving rise to serious side effects. Besides the clinical use of Sulfestrol the present invention also relates to oral dosage units comprising Sulfestrol and to sterile liquids for intravenous administration that comprise Sulfestrol.

Abstract: The present invention concerns the use of Fosfetrol (diethylstilbestrol diphosphate) in a method of curative or palliative treatment of cancer in female mammals, said method comprising orally administering Fosfestrol in a daily dosage of at least 500 mg. Examples of cancers that can be treated by the present method include breast cancer, endometrium cancer and ovarian cancer. The invention further provides an oral dosage unit containing at least 500 mg of Fosfestrol.

Abstract: The invention relates to the use of Sulfestrol (diethylstilbestrol sulfate) in a method of curative or palliative treatment of cancer in a mammal. The inventors have unexpectedly found that Sulfestrol can suitably be employed as an effective drug in the treatment of cancer in mammals. The inventors have further discovered that Sulfestrol can be administered even in high dosages without giving rise to serious side effects. Besides the clinical use of Sulfestrol the present invention also relates to oral dosage units comprising Sulfestrol and to sterile liquids for intravenous administration that comprise Sulfestrol.

Abstract: The present invention relates to the use of Fosfestrol (diethylstilbestrol diphosphate) in a method of curative or palliative treatment of prostate cancer in male mammals, said method comprising orally administering Fosfestrol in a daily dosage of at least 1,000 mg. The inventors have discovered that Fosfestrol when administered in very high oral dosages is effective in the treatment of prostate cancer, especially hormone resistant prostate cancer, without giving rise to serious side effects, such as thromboembolic toxicity or mortality. The invention further provides an oral dosage unit comprising at least 500 mg, of Fosfestrol.